Journal article
Radiation protection considerations with [ 89 Zr]Zr-girentuximab PET and surgery
EJNMMI research, Vol.15(1), 59
05/23/2025
DOI: 10.1186/s13550-025-01247-1
PMCID: PMC12102418
PMID: 40408016
Abstract
Zr is emerging as a popular positron-emitting radionuclide for imaging; however, its 909 keV gamma emission presents shielding challenges, and radiation exposure safety guidelines for healthcare professionals working with the radionuclide have not been well-established. To guide assessment of the radiation risk and necessary safety guidelines, we present laboratory dose rate measurements of
Zr syringes and vials, and dose rates measurements made during the ZIRCON clinical trial ([
Zr]Zr-girentuximab) to evaluate healthcare provider exposure during administration, imaging, and surgical procedures.
The maximum dose rate from a vial with no shielding was 0.334 µSv/h/MBq, and the minimum dose rate with 66 mm lead shielding was 0.004 µSv/h/MBq. The controlled spill measured 0.52 µSv/h/MBq. Dose rates 1 m from patients who received [
Zr]Zr-girentuximab had an average of 3.90 µSv/h at imaging. During surgery, waste measured below background levels, and a bed assistant 0.8 m from the patient received a 5 µSv/h whole-body dose rate. The excised kidney measured 6 µSv/h at 5 cm.
Our results demonstrate low radiation exposure levels associated with
Zr handling and exposure to the patient. With potential integration of
Zr into clinical practice, appropriate radiation safety guidelines are needed. Dose rate measurements can help guide development of best practices and site-specific protocols.
not applicable for this study; ZIRCON trial number NCT03849118, registered on 19 February 2019.
Details
- Title: Subtitle
- Radiation protection considerations with [ 89 Zr]Zr-girentuximab PET and surgery
- Creators
- Adnan Chowdhury - Royal Free London NHS Foundation TrustClément Morgat - Université de BordeauxClement Bailly - Centre National de la Recherche ScientifiqueJohn Sunderland - University of IowaStephen A Graves - University of IowaAndrew M Scott - The University of MelbourneSean Baker - Royal Free London NHS Foundation TrustBeverley F Holman - Royal Free London NHS Foundation Trust
- Resource Type
- Journal article
- Publication Details
- EJNMMI research, Vol.15(1), 59
- DOI
- 10.1186/s13550-025-01247-1
- PMID
- 40408016
- PMCID
- PMC12102418
- NLM abbreviation
- EJNMMI Res
- ISSN
- 2191-219X
- eISSN
- 2191-219X
- Publisher
- Springer
- Grant note
- Telix Pharmaceuticals: NCT03849118
The ZIRCON trial (NCT03849118) was sponsored by Telix Pharmaceuticals.
- Language
- English
- Date published
- 05/23/2025
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Radiology; Physics and Astronomy; Radiation Oncology
- Record Identifier
- 9984824329102771
Metrics
3 Record Views